TrialThe Lancet. Oncology2010

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Roy S Herbst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.